Physician profile
Peter Tek
NPI 1235403130
$6,764.81
in general payments reported to CMS, 2019-2025
54 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $473 · 2021: $948 · 2022: $1,548 · 2023: $706 · 2024: $928 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,637.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,332.94 | 2019-2023 | Xtandi, Myrbetriq |
| Coloplast Corp | $629.43 | 2019-2025 | Coloplast Tfl Drive |
| Antares Pharma, INC. | $310.23 | 2019-2025 | Xyosted |
| Boston Scientific Corporation | $300.80 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $289.13 | 2019-2025 | |
| Abbvie INC. | $273.41 | 2019-2025 | Botox, Lupron Depot |
| Olympus America INC. | $269.08 | 2021-2025 | Itind System, Soltive |
| Janssen Biotech, INC. | $256.17 | 2019-2025 | Erleada |
| Neotract INC. | $215.12 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $188.62 | 2019-2023 | Xiaflex, Edex, Aveed |
| Merck Sharp & Dohme LLC | $180.96 | 2022-2024 | Keytruda, Lynparza |
| Dendreon Pharmaceuticals LLC | $163.00 | 2019-2024 | Provenge |
| Novartis Pharmaceuticals Corporation | $147.39 | 2022-2025 | |
| Myovant Sciences INC. | $141.67 | 2021-2022 | |
| Urogen Pharma, INC. | $141.28 | 2020-2025 | Jelmyto |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Tek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.